



Vaccines and Global Health: The Week in Review
5 September 2020 :: Number 567
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 9,000 entries.

Comments and suggestions should be directed to

*David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org*

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]

- A. Milestones :: Perspectives :: Featured Journal Content
- B. [Emergencies](#)
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)



Milestones :: Perspectives :: Research

:::::

:::::

COVID-19 Vaccines – Development Status/Scorecard

321 vaccine candidates against COVID-19 now in development

04 Sep 2020 By CEPI

In April, CEPI researchers identified 115 vaccine candidates against COVID-19 that were at varying stages of development. In an update to this analysis, we report in Nature Reviews Drug Discovery that, in the space of 5 months, this number has nearly tripled to **321 vaccine candidates. 32 of which are now in clinical trials, including eight candidates backed by CEPI.**

Global progress in clinical trials and manufacturing

Progress towards a vaccine against COVID-19 has been truly global. **Of the 32 candidates that are in clinical trials, there are plans to enroll 280,000 trial participants from at least 470 sites in 34 different countries.**

Six clinical candidates are now in the most advanced phase III trials. These include two CEPI-supported candidates (AstraZeneca/Oxford and Moderna) and candidates that are being developed by Gamaleya Research Institute, Wuhan Institute of Biological Products/Sinopharm, Sinovac Biotech, and Pfizer/BioNTech.

For the leading candidates, large-scale manufacturing of vaccines has already been initiated to enable rapid distribution if approval is obtained. For CEPI's part, it has established manufacturing agreements with AstraZeneca/Oxford, The University of Queensland/CSL, Clover Biopharmaceuticals, Novavax and SK Bioscience.

Technology platforms and vaccine targets

A wide range of technology platforms are being used to develop COVID-19 vaccines, including both traditional and novel approaches.

Early data are emerging for the most advanced clinical candidates and although encouraging antibody and T-cell responses have been reported, it is too early to assess their relative potential...

:::::

:::::

COVID-19 Vaccines & Therapeutics – Industry Standards/Commitments

Biopharma industry updates on COVID-19 treatments progress and warns about upholding regulatory standards of quality – IFPMA

Geneva, 3 September 2020 – Seven months into the pandemic, the innovative biopharmaceutical industry continues to step up work on researching and testing therapeutics that could lower mortality rates or lessen the severity of COVID-19. Over recent months, the

results of rigorous clinical trials of repurposed medicines to achieve quick wins have been mixed, while the pipeline for new treatments does hold promise. Considerable efforts are going into planning to scale up and share manufacturing capacity should treatments prove safe and effective.

IFPMA is strongly committed to rigorous regulatory standards for approval of COVID-19 treatments and vaccines. No matter how urgently action is needed against the coronavirus public health emergency, it is imperative that the highest standards of quality, safety and efficacy are upheld everywhere. IFPMA member companies are fully committed to transparency in reporting clinical trial results whether these are good or bad; they support the need to inform the public of what they know, as well as what they don't know about the vaccines in development.

The innovative biopharmaceutical industry believes that ensuring the right level of engagement with society whilst assessing and approving vaccines will be key to gaining the public's trust in COVID-19 vaccines and helping end the coronavirus pandemic.

Vaccines may ultimately bring an end to the pandemic, but there is an urgent need for therapeutic innovation that can offer clinical benefits to COVID-19 patients. Today, more than [300 COVID-19 treatments](#) are being researched or are in clinical trials around the world: some repurposed medicines proven to work against other deadly diseases, others as novel as the virus itself.

Today, 22 leading IFPMA member companies are involved in R&D for therapeutics and together have enacted or are conducting 81 clinical trials evaluating therapeutics' effectiveness. The main COVID-19 treatments being looked at are antivirals, antibodies and convalescent plasma, as well as anti-inflammatories. This is encouraging as the clinical response to help patients with COVID-19 requires multiple treatment options but there is no magic bullet to treat or cure patients with the virus.

For some repurposed treatments, hopes have been dashed. Rigorous clinical trials have shown that hydroxychloroquine for patients with mild COVID-19 does not work. Tocilizumab has also proven to show no marked improvement in adult patients with severe COVID-19-associated pneumonia. In contrast, dexamethasone has proven effective in seriously ill COVID-19 patients. Researchers are now waiting for results of repurposed treatments used in combination.

Elsewhere, hopes have been fulfilled: remdesivir has gone in a matter of months from an investigational compound to an available therapy that shortens recovery times among hospitalized patients. Further down the line, other novel treatments may help patients with weakened immune systems. Progress is being made, but at a slower pace than society would have hoped for. Should a treatment prove safe or effective, biopharmaceutical companies are already planning upfront how to scale up and be ready to share manufacturing capacity in order to meet potential demand...

Thomas Cueni, Director General of IFPMA, commented on progress in finding treatments for COVID-19: "We're still on a learning curve. However, we remain on course with single-minded focus and a willingness to take on the risks inherent in all innovation while pulling together our R&D capabilities for the benefit of patients [living up to our commitments](#). What we've learnt so

far is that there will unlikely be a magic bullet for everyone against COVID-19, but that is no excuse for cutting corners in our haste to approve new treatments or vaccines."

:::::

BIO [to 5 Sep 2020]

<https://www.bio.org/press-releases>

Press Releases

Biotech Leaders Outline Principles to Ensure the "Public's Trust" in New Medical Products for Eradicating Covid-19

September 3, 2020

As America's researchers race to develop the scientific solutions needed to eradicate Covid-19, leaders within the Biotechnology Innovation Organization (BIO) [released an open letter](#) to their biopharmaceutical colleagues that articulates key principles to ensure the "integrity, transparency, and objective assessment" of Covid-19 clinical data and secure public trust in new medical products developed in response to the pandemic:

AN OPEN LETTER TO THE BIOPHARMACEUTICAL INDUSTRY

September 03, 2020

The biopharmaceutical industry is at the center of the world's fight against Covid-19, leading the effort to develop new vaccines, therapeutic medicines and diagnostics.

Over time, we expect these efforts to be successful, resulting in a range of new healthcare products for the benefit of the entire world. These new products will need to be manufactured in large quantities and distributed rapidly to all segments of our society. Physicians, public health officials, patients and healthy citizens will need to be educated as to their safety, efficacy, and risk/ benefit. Their widespread adoption will be based on trust in the integrity of the scientific and public health principles governing their development and approval.

If this is done correctly, we will halt the pandemic, save lives, reignite our economy and enable a return to a more normal life. We will emerge from this pandemic better prepared to address and react to future biological threats.

As data begin to emerge from clinical trials of an array of vaccines and therapeutics, we believe that it is important for us in the biopharmaceutical industry to articulate the principles we see as essential for assessing these data and determining their potential value. We believe that public health, and the public's trust in new medical products, are dependent upon the integrity, transparency and objective assessment of new data as they emerge.

Accordingly, we are articulating the following principles:

[1] Clinical trials should be conducted according to best practices to assure credibility of the data, as well as the ethical participation of a diverse population of subjects.

[2] Companies should disclose important clinical data via well-respected scientific meetings or rigorous, independent peer review journals. The disclosure of key scientific and clinical data through meetings and journals is the gold standard. However, companies may need to release some clinical data in advance of publication. In these instances, companies should approach any pre-publication press activity thoughtfully, and data should not be released by press release

alone. Sponsors should ensure that data included in any press statement are clear and include accurate descriptions of key data points while reinforcing that the full data will be submitted for peer review.

[3] FDA should maintain its historic independence as the gold-standard international regulatory body, free from external influence. This will assure the public that the FDA review process will adhere to the highest standards of scientific and medical integrity, and that any approved products therefore will meet the required standards of safety and efficacy.

[4] The appropriate use of any new products should be data-driven. Different sub-populations are likely to react differently to different medicines. These differences will begin to be revealed in larger long-term studies. The public should be assured that only rigorously considered data will dictate the subsequent use of any product. Distribution of any vaccines should be done with these considerations in mind.

[5] Political considerations should be put aside by Republicans and Democrats alike. Our nation's leaders should reassure the public that politics will not influence the development and approval of new medicines. Conclusions about both the safety and effectiveness of such medicines should be based on rigorous collection and assessment of data by all the appropriate bodies, and their distribution should be based on sound public health considerations. This approach is all the more vital considering the unprecedented pace and scale of the effort to develop treatments and vaccines for Covid-19.

We urge all parties involved in the development, review, approval, and distribution of COVID-19 therapeutics and vaccines to commit themselves to these principles.

Sincerely,
Jeremy M. Levin, DPhil, MB BChir
Chairman of the Board and CEO Ovid Therapeutics
Chair, Biotechnology Innovation Organization (BIO)

Paul J. Hastings
President and CEO Nkarta Therapeutics, Inc.
Vice Chair, Biotechnology Innovation Organization (BIO)

Ted W. Love, MD
President and CEO Global Blood Therapeutics
Chair, Emerging Companies Section Governing Board
Biotechnology Innovation Organization (BIO)

Michelle McMurry-Heath, MD, PhD
President and CEO
Biotechnology Innovation Organization (BIO)

Ron Cohen, MD
President and CEO Acorda Therapeutics, Inc.
Past Chair, Biotechnology Innovation Organization (BIO)

Rachel K. King
Founder and CEO GlycoMimetics, Inc.
Past Chair, Biotechnology Innovation Organization (BIO)

John Maraganore, PhD
CEO Alnylam Pharmaceuticals, Inc.
Past Chair, Biotechnology Innovation Organization (BIO)

Richard Pops
Chairman & CEO Alkermes, Inc.
Past Chair, Biotechnology Innovation Organization (BIO)

.....
.....

Featured Media Content

[**The Tragedy of Vaccine Nationalism**](#)

Only Cooperation Can End the Pandemic
Foreign Affairs September/October 2020
By Thomas J. Bollyky and Chad P. Bown
[Open Access]

Trump administration officials have compared the global allocation of vaccines against the coronavirus that causes COVID-19 to oxygen masks dropping inside a depressurizing airplane. "You put on your own first, and then we want to help others as quickly as possible," Peter Marks, a senior official at the U.S. Food and Drug Administration who oversaw the initial phases of vaccine development for the U.S. government, said during a panel discussion in June. The major difference, of course, is that airplane oxygen masks do not drop only in first class—which is the equivalent of what will happen when vaccines eventually become available if governments delay providing access to them to people in other countries...

...THE POWER OF FOMO

When the oxygen masks drop in a depressurizing plane, they drop at the same time in every part of the plane because time is of the essence and because that is the best way to ensure the safety of all onboard. The same is true of the global, equitable allocation of safe and effective vaccines against COVID-19.

Vaccine nationalism is not just morally and ethically reprehensible: it is contrary to every country's economic, strategic, and health interests. If rich, powerful countries choose that path, there will be no winners—ultimately, every country will be a loser. The world is not doomed to learn this the hard way, however. All the necessary tools exist to forge an agreement that would encourage cooperation and limit the appeal of shortsighted "my country first" approaches.

But time is running out: the closer the world gets to the day when the first proven vaccines emerge, the less time there is to set up an equitable, enforceable system for allocating them. As a first step, a coalition of political leaders from countries representing at least 50 percent of

global vaccine-manufacturing capacity must get together and instruct their public health officials and trade ministers to get out of their silos and work together. Combining forces, they should hammer out a short-term agreement that articulates the conditions for sharing, including with the legions of poorer, nonmanufacturing countries, and makes clear what would happen to participants who subsequently reneged and undertook vaccine nationalism. Such a step would get the ball rolling and convince even more of the manufacturing countries to sign on. The fear of missing out on vaccine access, in the event their countries' own vaccine candidates fail, may be what it takes to pressure even today's most reluctant leaders to cooperate.

:::::
:::::

COVID-19 Vaccines – Africa

[African countries engaging in ground-breaking COVID-19 vaccine initiative](#)

03 September 2020

Brazzaville – While the race to find safe and effective COVID-19 vaccines continues, **African countries are signing up to a ground-breaking initiative, which aims to secure at least 220 million doses of the vaccine for the continent, once licensed and approved.**

All 54 countries on the continent have expressed interest in COVAX, a global initiative which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO). The partners are working with governments and manufacturers to procure enough vaccine doses to protect the most vulnerable populations on the continent. Through the Gavi-coordinated COVAX Facility, the initiative seeks to ensure access for all: both higher and middle-income countries which will self-finance their own participation, and lower-middle income and low-income countries which will have their participation supported by the COVAX Advance Market Commitment (AMC).

There are eight countries in Africa that have agreed to self-finance their vaccine doses through the COVAX Facility. This expression of interest will turn into binding commitments to join the initiative by 18 September, with upfront payments to follow no later than 9 October 2020...

In addition, 46 countries in Africa are eligible for support from the financing instrument, the COVAX AMC which has raised approximately US\$ 700 million against an initial target of securing US\$ 2 billion seed funding from high-income donor countries, as well as private sector and philanthropists by the end of 2020.

"COVAX is a ground-breaking global initiative which will include African countries and ensure they are not left at the back of the queue for COVID-19 vaccines," said Dr Matshidiso Moeti, WHO Regional Director for Africa. "By reaching beyond the continent to work together with other governments and manufacturers on a global scale and pooling buying power, countries can protect the people most vulnerable to the disease in Africa."...

"It's critical that countries in Africa participate in vaccine trials, in addition to the clinical trials taking place in other regions of the world," said Dr Richard Hatchett, Chief Executive Officer, CEPI. "Testing vaccines on the continent ensures that

sufficient data is generated on the safety and efficacy of the most promising vaccine candidates for the African population so they can be confidently rolled out in Africa once vaccines are approved. CEPI is investing in the research and development of a diverse range of vaccine candidates, with the aim of delivering safe and effective vaccines to those who need them most through COVAX."

Through COVAX, vaccines that have passed regulatory approval or WHO prequalification will be delivered equally to all participating countries, proportional to their populations. Health workers and other vulnerable populations will be prioritized and then vaccine availability will expand to cover additional priority populations in participating countries.

African countries will need to have in place the right systems and infrastructure to define the regulatory and ethical pathways for a quick approval of a candidate vaccine. They will need to have logistics and supply chain systems which can reach not only the traditional target populations for routine immunizations and campaigns but be ready to vaccinate a much larger target population.

"To roll out a vaccine effectively across countries in Africa, it is critical that communities are engaged and understand the need for vaccination," said Dr Richard Mihigo, Programme Area Manager, Immunization and Vaccine Development, Programme Area Manager, Immunization and Vaccine Development, WHO Regional Office for Africa. "It is important to already start working with communities to prepare the way for one of the largest vaccination campaigns Africa has ever experienced."...

:::::
:::::

COVID-19 – Health Services Impacts

In WHO global pulse survey, 90% of countries report disruptions to essential health services since COVID-19 pandemic

WHO to roll out learning and monitoring tools to improve service provision during pandemic
31 August 2020 *News release*

The World Health Organization (WHO) today published a first indicative survey on the impact of COVID-19 on health systems based on 105 countries' reports. **Data collected from five regions over the period from March to June 2020 illustrate that almost every country (90%) experienced disruption to its health services, with low- and middle-income countries reporting the greatest difficulties.** Most countries reported that many routine and elective services have been suspended, while critical care - such as cancer screening and treatment and HIV therapy – has seen high-risk interruptions in low-income countries.

"The survey shines a light on the cracks in our health systems, but it also serves to inform new strategies to improve healthcare provision during the pandemic and beyond," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "COVID-19 should be a lesson to all countries that health is not an 'either-or' equation. We must better prepare for emergencies but also keep investing in health systems that fully respond to people's needs throughout the life course."

Services hit across the board: Based on reports from key informants, countries on average experienced disruptions in 50% of a set of 25 tracer services. **The most frequently disrupted areas reported included routine immunization – outreach services (70%) and facility-based services (61%)**, non-communicable diseases diagnosis and treatment (69%), family planning and contraception (68%), treatment for mental health disorders (61%), cancer diagnosis and treatment (55%).

Countries also reported disruptions in malaria diagnosis and treatment (46%), tuberculosis case detection and treatment (42%) and antiretroviral treatment (32%). While some areas of health care, such as dental care and rehabilitation, may have been deliberately suspended in line with government protocols, the disruption of many of the other services is expected to have harmful effects on population health in the short- medium- and long-term.

Potentially life-saving emergency services were disrupted in almost a quarter of responding countries. Disruptions to 24-hour emergency room services for example were affected in 22% of countries, urgent blood transfusions were disrupted in 23% of countries, emergency surgery was affected in 19% of the countries.

Disruption due to a mix of supply and demand side factors. 76% of countries reported reductions in outpatient care attendance due to lower demand and other factors such as lockdowns and financial difficulties. The most commonly reported factor on the supply side was cancellation of elective services (66%). Other factors reported by countries included staff redeployment to provide COVID-19 relief, unavailability of services due to closings, and interruptions in the supply of medical equipment and health products...

:::::

:::::

EMERGENCIES

Coronavirus [COVID-19]

Public Health Emergency of International Concern (PHEIC)

Weekly Epidemiological and Operational updates August 2020

Confirmed cases :: 26 468 031 [week ago: 24 587 513]

Confirmed deaths :: 871 166 [week ago: 833 556]

Weekly Epidemiological Update

Coronavirus disease 2019 (COVID-19)

4 September 2020

WHO response in countries

3 September 2020

A live digital Platform behind the scenes for more effective and transparent country response

2 September 2020

[WHO updates clinical care guidance with corticosteroid recommendations](#)

31 August 2020

[Athens protects vulnerable communities during COVID-19](#)

:::::

:::::

[Emergencies](#)

POLIO

Public Health Emergency of International Concern (PHEIC)

[Polio this week as of 03 September 2020](#)

:: The Polio Oversight Board (POB) released a statement [see below] after holding a meeting on 18 August 2020 where they reviewed progress on resumption of vaccination campaigns after the Covid-19 induced pause, programme transformation in Pakistan, the increase in circulating Vaccine Derived Polio Virus (cVDPV) outbreaks, and the financial situation.

:: Professor Rose Leke, an infectious disease specialist, has been the chairperson of the ARCC since it was set up in 1998. A trailblazer for women in global health, Leke has fought throughout her career to improve women's representation in science and global health leadership. [Take a look](#) at her journey in polio eradication and her views on gender and women in science.

Summary of new WPV and cVDPV viruses this week (AFP cases and environmental samples):

:: Afghanistan: Three WPV1 cases, one WPV1 positive environmental sample and 13 cVDPV2 cases

:: Pakistan: Five WPV1 positive environmental samples and three cVDPV2 positive environmental samples

:: Cameroon: one cVDPV2 positive environmental sample

:: Chad: three cVDPV2 cases

:: Democratic Republic of the Congo (DR Congo): one cVDPV2 case

:::::

[Statement: POLIO OVERSIGHT BOARD – 24 August 2020](#)

Meeting of 18 August 2020

On August 18, the Polio Oversight Board (POB) of the Global Polio Eradication Initiative (GPEI) convened to assess the status of polio eradication. The Board reviewed progress on resumption of vaccination campaigns after the Covid-19 induced pause, programme transformation in Pakistan, the increase in circulating Vaccine Derived Polio Virus (cVDPV) outbreaks, and the financial situation. The discussion was informed by the recent reports of the Independent Monitoring Board, the Pakistan and Afghanistan Technical Advisory Groups and the participation of major donors.

The COVID-19 pandemic impacted the polio eradication programme with paused campaigns, disruption of essential immunization and a decline in surveillance

quality. The Board was humbled by the commitment of front-line polio staff to respond to the COVID-19 pandemic and who also recognized the importance of safely restarting campaigns to deliver polio vaccines in communities while the COVID virus circulates.

The pandemic demonstrates the critical role of GPEI funded staff for global health security and underlined the importance of integrating functions into the broader immunization and emergencies infrastructure to ensure the critical public health workforce remains a global asset even after the world has eradicated polio.

Agility, innovation and discipline, driven by a focus on activities on the critical path to polio eradication, are needed to offset the impact of the COVID-19 pandemic. GPEI will re-establish high-quality surveillance, intensify access negotiations in Afghanistan, accelerate the transformation of the Pakistan programme, and facilitate the resumption of immunization campaigns emphasizing the delivery of additional interventions when and where possible.

In view of the dynamic challenges faced, the POB approved a process to revise the 2019-2023 Polio Eradication Strategy and related budget, including the establishment of an external advisory group to advise on its content. To ensure that GPEI is best positioned to implement the revised strategy, the Board requested quick action on the Governance Review and complementary management review.

The Board reviewed with great concern the financial status of the Polio programme. Appreciating the generous pledges of support announced in Abu Dhabi in November 2019, programmatic developments have put acute pressure on available resources. These developments include the setbacks in interrupting wild poliovirus in the two remaining polio endemic countries, a marked increase of cVDPV outbreaks, additional costs of infection prevention in the context of COVID-19 and the need to catch up on paused campaigns. This is compounded by economic impacts of the pandemic globally, which constrain financial resources and political attention in both programme and donor countries, leading to an anticipated substantial shortfall between resources required and resources available in 2021.

The Polio Oversight Board reviewed a plan to optimize the use of available and projected resources in 2021 and agreed that efficiencies can be realized. **Board members also expressed concern that the level of risk associated with some of the proposed programmatic reductions could jeopardize both the gains and investments of the last 30 years and impede success. As an immediate step, GPEI will implement low risk-high return efficiency savings and strive to integrate efforts with other health interventions.** The Board committed to advocating to increase national ownership and commitment, to raise the additional resources needed to meet urgent programme requirements and to intensify the response to the extraordinary challenges that have arisen, including exploring the use of COVID-19 resources where appropriate.

The POB reaffirmed the unequivocal commitment of GPEI partners to achieving global polio eradication.

The Board thanks all stakeholders for their commitment and support that has brought polio so close to eradication. We urge all partners and countries to continue to invest both human and

financial resources in polio eradication and essential immunization so that no child needs suffer paralysis from this preventable disease.

:::::
::::

Emergencies

Ebola – DRC+

Public Health Emergency of International Concern (PHEIC)

Last *WHO Situation Report* published 23 June 2020

:::::
::::

WHO Grade 3 Emergencies [to 5 Sep 2020]

Democratic Republic of the Congo - *No new digest announcements identified*
Mozambique floods - *No new digest announcements identified*
Nigeria - *No new digest announcements identified*
Somalia - *No new digest announcements identified*
South Sudan - *No new digest announcements identified*
Syrian Arab Republic - *No new digest announcements identified*
Yemen - *No new digest announcements identified*

::::

WHO Grade 2 Emergencies [to 5 Sep 2020]

Measles in Europe

::: Unleashing the potential of vaccines for a healthier Europe 02-09-2020

Afghanistan - *No new digest announcements identified*
Angola - *No new digest announcements identified*
Burkina Faso [in French] - *No new digest announcements identified*
Burundi - *No new digest announcements identified*
Cameroon - *No new digest announcements identified*
Central African Republic - *No new digest announcements identified*
Ethiopia - *No new digest announcements identified*
Iran floods 2019 - *No new digest announcements identified*
Iraq - *No new digest announcements identified*
Libya - *No new digest announcements identified*
Malawi - *No new digest announcements identified*
MERS-CoV - *No new digest announcements identified*
Myanmar - *No new digest announcements identified*
Niger - *No new digest announcements identified*
occupied Palestinian territory - *No new digest announcements identified*
HIV in Pakistan - *No new digest announcements identified*
Sao Tome and Principe Necrotizing Cellulitis (2017) - *No new digest announcements identified*

Sudan - No new digest announcements identified
Ukraine - No new digest announcements identified
Zimbabwe - No new digest announcements identified

:::::

WHO Grade 1 Emergencies [to 5 Sep 2020]
Chad - No new digest announcements identified
Djibouti - Page not responding at inquiry
Kenya - No new digest announcements identified
Mali - No new digest announcements identified
Namibia - viral hepatitis - No new digest announcements identified
Tanzania - No new digest announcements identified

:::::

:::::

UN OCHA – L3 Emergencies

The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.

Syrian Arab Republic

:: Syrian Arab Republic: COVID-19 Humanitarian Update No. 17 As of 1 September 2020

Yemen

:: 03 September 2020 Yemen Situation Report, 3 Sep 2020
- Torrential rains cause devastation across Yemen for the third time this year
- COVID-19 response to be pivoted
- Fuel crisis seriously holds back the humanitarian response in northern governorates
- Stranded migrants in Yemen in desperate need of humanitarian assistance
- Locust infestations threaten to exacerbate food insecurity in Yemen

:::::

UN OCHA – Corporate Emergencies

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

COVID-19

:: Coronavirus disease 2019 (COVID-19) Situation Report 42: occupied Palestinian territory, issued 3 September 2020, information for period: 5 March - 3 September 2020

East Africa Locust Infestation

:: Desert Locust situation update - 2 September 2020

:::::

:::::

WHO & Regional Offices [to 5 Sep 2020]

3 September 2020 *Departmental news*

WHO convenes expert group for behaviour change

31 August 2020 *News release*

In WHO global pulse survey, 90% of countries report disruptions to essential health services since COVID-19 pandemic

[See Milestones above for detail]

:::::

Weekly Epidemiological Record, 4 September 2020, vol. 95, 36 (pp. 417–440)

Global leprosy (Hansen disease) update, 2019: time to step-up prevention initiatives
COVID-19 update

:::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

- :: 04 September 2020 Decisive and timely: Mauritius' response curbs COVID-19
- :: 03 September 2020 African countries engaging in ground-breaking COVID-19 vaccine initiative

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

- :: Europe lights the way for schooling during the COVID-19 pandemic and beyond 04-09-2020
- :: Unleashing the potential of vaccines for a healthier Europe 02-09-2020
- :: Athens protects vulnerable communities during COVID-19 01-09-2020
- :: Towards a consensus on safe schooling in the WHO European Region during the COVID-19 pandemic 31-08-2020

WHO Eastern Mediterranean Region EMRO

- :: Statement by WHO's Regional Director on an upsurge in the number of COVID-19 cases in the Eastern Mediterranean Region

3 September 2020 – Our Region is close to approaching a new grim milestone of 2 million COVID-19 cases: as of 1 September, the cumulative number of cases in the Region is now more than 1 936 221, with 51 326 deaths. Of greatest concern is a new upsurge in cases in a number of countries, highlighting the negative consequences of lack of adherence to public health measures....

WHO Western Pacific Region

- :: Protecting older people against COVID-19 3 September 2020

:::::
:::::

CDC/ACIP [to 5 Sep 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases

No new digest content identified

:::::

MMWR News Synopsis Friday, September 4, 2020

Timing of State and Territorial COVID-19 Stay-at-Home Orders and Changes in Population Movement — United States, March 1–May 31, 2020

Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment — United States, January–June 2020

Preventing and Mitigating SARS-CoV-2 Transmission — Four Overnight Camps, Maine, June–August 2020 (Early release August 26, 2020)

Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network — 13 Academic Medical Centers, April–June 2020 (Early release August 31, 2020)

:::::

Africa CDC [to 5 Sep 2020]

<http://www.africacdc.org/>

News

Press Releases

Training of trainers on infection prevention and control for COVID-19 concludes in DRC

2 September 2020

Press Releases

Africa CDC launches web-based tool to better manage public health emergency workforce deployments

1 September 2020

Press Releases

Team Europe: Germany and European Union jointly support African Union's response to COVID-19

1 September 2020

:::::

China CDC

<http://www.chinacdc.cn/en/>

No new digest content identified.

National Health Commission of the People's Republic of China

<http://en.nhc.gov.cn/>

News

Sept 5: Daily briefing on novel coronavirus cases in China

On Sept 4, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland **reported 10 new cases of confirmed infections**.

Expert: More second infection cases possible but with proper self-protection, no need to be too nervous

2020-09-02

Four Chinese COVID-19 vaccines undergoing phase-3 clinical trials

2020-08-31

BEIJING -- Four Chinese COVID-19 vaccine candidates have started international phase-3 clinical trials, according to the State Council joint prevention and control mechanism against COVID-19.

Some of the phase-3 trials are expected to complete the first round of vaccinations in early September, with preliminary data expected as early as November.

Phase-3 clinical trials usually involve thousands of people to verify the safety and effectiveness of the vaccines, which are key to their market approval.

As the epidemic has been brought under control in China, the country no longer has conditions for large-scale clinical trials, so all the phase-3 trials are being carried out overseas.

Two inactivated COVID-19 vaccines developed by the China National Biotec Group (CNBG) have been approved for phase-3 clinical trials in several countries in the Middle East and South America, involving more than 30,000 people, according to Yang Xiaoming, president of the CNBG...

.....
.....

Announcements

Paul G. Allen Frontiers Group [to 5 Sep 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 5 Sep 2020]

<https://www.phe.gov/about/barda/Pages/default.aspx>

BARDA News

No new digest content identified.

BMGF - Gates Foundation [to 5 Sep 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 5 Sep 2020]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 5 Sep 2020]

<https://carb-x.org/>

CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 5 Sep 2020]

<http://cepi.net/>

Latest News

321 vaccine candidates against COVID-19 now in development

04 Sep 2020 By CEPI

[See COVID-19 Vaccines above for detail]

EDCTP [to 5 Sep 2020]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

Latest news

No new digest content identified.

Emory Vaccine Center [to 5 Sep 2020]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Medicines Agency [to 5 Sep 2020]

<http://www.ema.europa.eu/ema/>

News & Press Releases

News: EMA receives application for marketing authorisation of Dexamethasone Taw for COVID-19

Last updated: 02/09/2020

News: EMA starts review of dexamethasone for treating adults with COVID-19 requiring respiratory support (updated)

CHMP, Last updated: 02/09/2020

European Vaccine Initiative [to 5 Sep 2020]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified.

FDA [to 5 Sep 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

Press Announcements

September 4, 2020 - Coronavirus (COVID-19) Update: Daily Roundup September 4, 2020

... The FDA issued an updated [FDA COVID-19 Response At-A-Glance Summary](#) that provides a quick look at facts, figures, and highlights of the agency's response efforts...

September 3, 2020 - Coronavirus (COVID-19) Update: Daily Roundup September 3, 2020

September 2, 2020 - Coronavirus (COVID-19) Update: Daily Roundup September 2, 2020

...Today, the FDA updated its guidance, "[Investigational COVID-19 Convalescent Plasma](#)," to provide additional information related to the recently issued Emergency Use Authorization (EUA) for the use of COVID-19 convalescent plasma to treat hospitalized patients with COVID-19. This update includes a discussion regarding FDA's intent to exercise temporary enforcement discretion regarding the IND requirements for the use of this product when blood establishments, hospitals, and health care providers collect plasma that does not meet the Conditions of Authorization of the EUA. The revised guidance continues to provide recommendations for health care providers who wish to administer and study convalescent plasma under an Investigational New Drug Application. In addition, the agency updated the web page, "[Recommendations for Investigational COVID-19 Convalescent Plasma](#)," which also provides this information....

September 1, 2020 - Coronavirus (COVID-19) Update: Daily Roundup September 1, 2020

August 31, 2020 - Coronavirus (COVID-19) Update: Daily Roundup August 31, 2020

... he FDA broadened the scope of the existing [emergency use authorization \(EUA\)](#) for the drug Veklury (remdesivir) to include treatment of all hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19, irrespective of their severity of disease...

Fondation Mérieux [to 5 Sep 2020]

<http://www.fondation-merieux.org/>

News, Events

Mérieux Foundation co-organized event

ACDx Webinar focused on the critical role of diagnostics in the COVID-19 pandemic – 4 regional perspectives

September 15, 2020 - Webinar 3:00pm to 5:00pm (CET)

The COVID-19 pandemic has highlighted the major role of diagnostics in the patient's management. Around the globe, the regions and countries have put in place different diagnostics strategies and policies to tackle this COVID-19 sanitary crisis.

The Mérieux Foundation and the London School of Hygiene & Tropical Medicine (LSHTM) are jointly organizing a 2 hour webinar on September 15 at 3pm (CET) on the critical role of diagnostics in the COVID-19 crisis management to share best practices & lessons learnt from experiences around the world.

Gavi [to 5 Sep 2020]

<https://www.gavi.org/>

News releases

No new digest content identified.

GHIT Fund [to 5 Sep 2020]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that

No new digest content identified.

Global Fund [to 5 Sep 2020]

<https://www.theglobalfund.org/en/news/>

News/Updates

News

Qatar Increases its Contribution to the Global Fund Fivefold

03 September 2020

Qatar and the Global Fund today signed a multi-year contribution agreement for US\$50 million for 2020-2022, strengthening their partnership in fighting infectious diseases and in building resilient systems for health.

Hilleman Laboratories [to 5 Sep 2020]

<http://www.hillemanlabs.org/>

No new digest content identified.

Human Vaccines Project [to 5 Sep 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

Press Release

No new digest content identified.

IAVI [to 5 Sep 2020]
<https://www.iavi.org/newsroom>
FEATURES
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
<http://www.icmra.info/drupal/en/news>
Selected Statements, Press Releases, Research
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
<https://www.igbamedicines.org/>
News
No new digest content identified.

IFFIm
<http://www.iffim.org/>
Announcements
No new digest content identified.

IFRC [to 5 Sep 2020]
<http://media.ifrc.org/ifrc/news/press-releases/>
Selected Press Releases, Announcements
Americas, Bahamas
[Hurricane Dorian anniversary: Thousands supported during a global pandemic and in the midst of hurricane season](#)
Panama/Geneva, 1 September 2020 — One year after Hurricane Dorian devastated communities in the Bahamas, the Red Cross has assisted thousands of families with emergency relief, financial assistance and support for long-term recovery.

IRC International Rescue Committee [to 5 Sep 2020]
<http://www.rescue.org/press-release-index>
Media highlights {Selected}
Press Release
[COVID-19 cases increase 220% in month since Beirut explosion](#)
September 1, 2020

IVAC [to 5 Sep 2020]
<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

Webinar: Avoiding Barriers to Access for a COVID-19 Vaccine

Register: The International Vaccine Access Center (IVAC) on September 16, 2020 at 8:00 EDT/21:00 KST will host a 60-minute webinar, ["Avoiding Barriers to Access for a COVID-19 Vaccine."](#)

Description: Even before the COVID-19 pandemic, countries worked to overcome a myriad of challenges when introducing new safe and effective vaccines. While policy makers and health advocates addressed barriers, from understanding disease burden and cost effectiveness to establishing cold chain systems, preventable diseases spread, sicken populations, and cost lives. Learning from the past failures of vaccine introductions will be crucial for ensuring equitable access to a COVID-19 vaccine. Leaders and scientists in the international vaccine field will discuss the barriers to vaccine access we must overcome to avoid and the role the international community will play in promoting equity in delivering a COVID-19 vaccine.

IVI [to 5 Sep 2020]

<http://www.ivi.int/>

Selected IVI News & Announcements

No new digest content identified.

JEE Alliance [to 5 Sep 2020]

<https://www.jeealliance.org/>

Selected News and Events

No new digest content identified.

MSF/Médecins Sans Frontières [to 5 Sep 2020]

<http://www.msf.org/>

Latest [Selected Announcements]

Lebanon

"The explosion did not distinguish between its victims and neither shou...

Interview 4 Sep 2020

DRC Ebola outbreaks

Crisis update - September 2020

Crisis Update 4 Sep 2020

DRC Ebola outbreaks

Responding to new Ebola outbreak in Équateur province

Project Update 4 Sep 2020

Coronavirus COVID-19 pandemic

Greek police enforce unwarranted and cruel quarantine of Moria camp ...

Statement 3 Sep 2020

Mediterranean migration

Sea-Watch 4 is allocated a port of safety 11 days after first rescue

Interview 2 Sep 2020

Nigeria

"When I think about going home, I remind myself that a live dog is better than a ...

Voices from the Field 1 Sep 2020

Cameroon

A hospital at the heart of the North-West crisis in Cameroon

Project Update 1 Sep 2020

National Vaccine Program Office - U.S. HHS [to 5 Sep 2020]

<https://www.hhs.gov/vaccines/about/index.html>

NVAC Meetings

September 23-24, 2020 Meeting (Virtual)

February 4-5, 2021 NVAC Meeting

June 16-17, 2021 NVAC Meeting

NIH [to 5 Sep 2020]

<http://www.nih.gov/news-events/news-releases>

Selected News Releases

NIH continues to boost national COVID-19 testing capacity

September 2, 2020 — New laboratory and point-of-care tests to enable access and rapid result.

NIH-supported study to track prevalence and impact of SARS-CoV-2 among pregnant women in low- and middle-income countries

September 1, 2020 — The study will follow women through pregnancy and 12 months after childbirth.

Phase 3 Clinical Testing in the US of AstraZeneca COVID-19 Vaccine Candidate Begins

August 31, 2020 — The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States to evaluate if the candidate vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19).

People with intellectual and developmental disabilities disproportionately affected by COVID-19

August 28, 2020 — NIH-funded researchers call for restoration of support services or alternatives.

PATH [to 5 Sep 2020]

<https://www.path.org/media-center/>

Press Releases

Expanding access to HPV vaccines: PATH to evaluate safety and immunogenicity of new HPV vaccine

August 31, 2020 by Tara Newton

PATH, Innovax, KfW, and the Bill & Melinda Gates Foundation are partnering to expand options for human papillomavirus (HPV) vaccines in the countries that need them most.

Sabin Vaccine Institute [to 5 Sep 2020]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 5 Sep 2020]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

4 September 2020

[Guyana's HIV food bank comes to the rescue during COVID-19](#)

4 September 2020

[Evaluation of UNFPA support to the HIV response](#)

UNICEF [to 5 Sep 2020]

<https://www.unicef.org/media/press-releases>

Selected Press releases/Announcements

Press release

09/03/2020

[UNICEF to lead procurement and supply of COVID-19 vaccines in world's largest and fastest ever operation of its kind](#)

UNICEF will work with manufacturers and partners on the procurement of vaccine doses as well as freight, logistics and storage of COVID-19 vaccines, on behalf of global COVAX Facility

Press release

09/03/2020

[Increased support vital to help children affected by Beirut explosions back to school, one month after devastating explosions](#)

183 education facilities damaged or destroyed by the blasts, affecting over 77,000 children and youth as new school year approaches

Press release

09/03/2020

[World's richest countries grappling with children's reading and math skills, mental well-being and obesity](#)

New report ranks the Netherlands, Denmark and Norway the best among EU and OECD countries for child wellbeing; and highlights substantial threats to child well-being due to the COVID-19 pandemic

Press release

09/01/2020

Business, government, multilateral agency and UN leaders commit to connecting children and young people to the internet by 2030

As half the world's population remain unconnected, a virtual 'Generation Unlimited' event calls for urgent action and investment to bridge the digital divide and scale-up digital learning and skilling opportunities

Unitaid [to 5 Sep 2020]

<https://unitaid.org/>

Featured News

03 September 2020 | *Press releases*

Life-saving infant oxygen device awarded Unitaid funding

Vaccination Acceptance Research Network (VARN) [to 5 Sep 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 5 Sep 2020]

<http://www.vaccineconfidence.org/>

Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 5 Sep 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

No new digest content identified.

Wellcome Trust [to 5 Sep 2020]

<https://wellcome.ac.uk/news>

No new digest content identified.

The Wistar Institute [to 5 Sep 2020]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 5 Sep 2020]

<https://www.wfpha.org/>

Latest News

No new digest content identified.

World Organisation for Animal Health (OIE) [to 5 Sep 2020]

<https://www.oie.int/en/for-the-media/press-releases/2020/>

Press Releases

No new digest content identified.

:::::

ARM [Alliance for Regenerative Medicine] [to 5 Sep 2020]

<https://alliancerm.org/press-releases/>

Press Releases

[The Alliance for Regenerative Medicine Applauds New Rule From the Centers for Medicare & Medicaid Services Promoting Access to Innovative Therapies](#)

Washington, DC September 2, 2020

The Alliance for Regenerative Medicine (ARM) applauds the Centers for Medicare and Medicaid Services' (CMS) decision to finalize a new diagnosis-related group (DRG) for chimeric antigen receptor T cell (CAR-T) therapies in their FY21 Inpatient Prospective Payment System (IPPS) rule. This is a crucial step forward for patient access to life-changing therapies, and the result of multi-year collaboration among ARM, its members, regulators, and a diverse group of other stakeholders.

BIO [to 5 Sep 2020]

<https://www.bio.org/press-releases>

Press Releases

[Biotech Leaders Outline Principles to Ensure the “Public’s Trust” in New Medical Products for Eradicating Covid-19](#)

September 3, 2020

[See COVID-19 Vaccines above for detail]

DCVMN – Developing Country Vaccine Manufacturers Network [to 5 Sep 2020]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 5 Sep 2020]

<https://internationalbiotech.org/>

News

No new digest content identified.

IFPMA [to 5 Sep 2020]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

[Biopharma industry updates on COVID-19 treatments progress and warns about upholding regulatory standards of quality](#)

03 September 2020

[See COVID-19 Vaccines above for detail]

PhRMA [to 5 Sep 2020]

<http://www.phrma.org/>

Selected Press Releases, Statements

[Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi](#)

Stephen J. Ubl | September 2, 2020

Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections. I had the opportunity to connect with Paul Hudson, CEO of Sanofi, about the fight against COVID-19.

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Infection Control

September 2020 Volume 48, Issue 9, p975-1132

<http://www.ajicjournal.org/current>

Major Articles

[COVID-19 infection: Strategies on when to discontinue isolation, a retrospective study](#)

Amelita Woodruff, Katherine L Walsh, Dacre Knight, Joan M. Irizarry-Alvarado

p1032-1036

Published online: July 4, 2020

[Hand sanitizers: A review of ingredients, mechanisms of action, modes of delivery, and efficacy against coronaviruses](#)

Andrew P. Golin, Dexter Choi, Aziz Ghahary

p1062-1067

Published online: June 18, 2020

State of the Science Review

[Reducing antibiotic prescribing and addressing the global problem of antibiotic resistance by targeted hygiene in the home and everyday life settings: A position paper](#)

Jean-Yves Maillard, Sally F. Bloomfield, Patrice Courvalin, Sabiha Y. Essack, Sumanth Gandra, Charles P. Gerba, Joseph R. Rubino, Elizabeth A. Scott
p1090–1099

Published online: April 17, 2020

American Journal of Preventive Medicine

September 2020 Volume 59, Issue 3, p309-468

<http://www.ajpmonline.org/current>

Research Articles

[Human Papillomavirus Immunization in Rural Primary Care](#)

Rose Gunn, Laura K. Ferrara, Caitlin Dickinson, Isabel Stock, Jennifer Griffith-Weprin, Amy Wiser, Brigit Hatch, L.J. Fagnan, Patricia A. Carney, Melinda M. Davis
p377–385

Published online: June 27, 2020

[Physicians' Use of Evidence-Based Strategies to Increase Adult Vaccination Uptake](#)

Laura P. Hurley, Megan C. Lindley, Mandy A. Allison, Sean T. O'Leary, Lori A. Crane, Michaela Brtnikova, Brenda L. Beaty, Allison Kempe
e95–e103

Published online: May 21, 2020

American Journal of Public Health

September 2020 110(9)

<http://ajph.aphapublications.org/toc/ajph/current>

IMMIGRATION

[Immigrants and Access to Care: Public Health Must Lead the Way in Changing the Nation's Narrative](#)

Chronic Disease, Cardiovascular Disease, Immigration, Health Policy, Race/Ethnicity, Hispanics/Latinos, Health Service Delivery, Access to Care
Maia Ingram

PUBLIC SERVICE

[Incentivized Public Service Response to COVID-19 in Rural and Marginalized Urban Communities](#)

Rural Health, Public Health Workers, Health Policy, Community Health, Health Service Delivery
Irene Torres, Daniel F. López-Cevallos and Fernando Sacoto
110(9), pp. 1344–1345

DEMOCRACY

[COVID-19 Emergency Measures Are Hurting Democracy Globally](#)

Global Health, Government, Human Rights, Health Law, Injury/Emergency Care/Violence
Stephen Thomson and Eric C. Ip
110(9), pp. 1356–1357

American Journal of Tropical Medicine and Hygiene

Volume 103, Issue 3, September 2020
<http://www.ajtmh.org/content/journals/14761645/103/3>
[New issue; No digest content identified]

Annals of Internal Medicine
1 September 2020 Volume 173, Issue 5
<http://annals.org/aim/issue>
[New issue; No digest content identified]

Artificial Intelligence – An International Journal
Volume 287 October 2020
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/287/suppl/C>
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
<http://resource-allocation.biomedcentral.com/>
(Accessed 5 Sep 2020)
[No new digest content identified]

BMJ Global Health
September 2020 - Volume 5 - 9
<https://gh.bmj.com/content/5/9>
[New issue; No digest content identified]

BMC Health Services Research
<http://www.biomedcentral.com/bmchealthservres/content>
(Accessed 5 Sep 2020)
[No new digest content identified]

BMC Infectious Diseases
<http://www.biomedcentral.com/bmcinfectdis/content>
(Accessed 5 Sep 2020)
[The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines](#)
Maternal poliovirus antibodies could provide passive immunity to the newborns from poliovirus infection during their first few months of life, but they may impair the immune responses of infants to the poliovirus vaccine as well. In our study, we pooled the data from three clinical trials of the inactivated poliovirus vaccine (IPV) based on Sabin strains to investigate the effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines.
Authors: Siyue Jia, Rong Tang, Guifan Li, Yuemei Hu and Qi Liang
Citation: BMC Infectious Diseases 2020 20:641
Content type: Research article

Published on: 31 August 2020

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 5 Sep 2020)

South Africa's new standard material transfer agreement: proposals for improvement and pointers for implementation

Whenever South African (SA) research institutions share human biological material and associated data for health research or clinical trials they are legally compelled to have a material transfer agreement (MTA) in place that uses as framework the standard MTA newly gazetted by the South African Minister of Health (SA MTA).

Authors: Donrich W. Thaldar, Marietjie Botes and Annelize Nienaber

Citation: BMC Medical Ethics 2020 21:85

Content type: Debate

Published on: 3 September 2020

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 5 Sep 2020)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 5 Sep 2020)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 5 Sep 2020)

Spatial distribution of incomplete immunization among under-five children in Ethiopia: evidence from 2005, 2011, and 2016 Ethiopian Demographic and health survey data

An estimate of 2–3 million children under 5 die in the world annually due to vaccine-preventable disease. In Ethiopia, incomplete immunization accounts for nearly 16% of under-five mortality, and there is spat...

Authors: Mequannent Sharew Melaku, Araya Mesfin Nigatu and Wondewossen Zemene Mewosha

Citation: BMC Public Health 2020 20:1362

Content type: Research article

Published on: 5 September 2020

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 5 Sep 2020)
[No new digest content identified]

BMJ Open

August 2020 - Volume 10 – 8-9
<https://bmjopen.bmjjournals.org/content/10/8?current-issue=y>
[Reviewed earlier]

Bulletin of the World Health Organization

Volume 98, Number 9, September 2020, 581-644
<https://www.who.int/bulletin/volumes/98/9/en/>
EDITORIALS

[Gaps in access to essential medicines and health products for noncommunicable diseases and mental health conditions](#)

— Ren Minghui, Mariangela Simao, Bente Mikkelsen, Dévora Kestel, Andrew Ball & Zsofia Szilagyi
<http://dx.doi.org/10.2471/BLT.20.272658>

[COVID-19 response measures and violence against children](#)

— Amiya Bhatia, Camilla Fabbri, Ilan Cerna-Turoff, Clare Tanton, Louise Knight, Ellen Turner, Michelle Lokot, Shelley Lees, Ben Cislaghi, Amber Peterman, Alessandra Guedes & Karen Devries
<http://dx.doi.org/10.2471/BLT.20.263467>

PERSPECTIVES

[Accelerating access to medicines in a changing world](#)

— Hannah Kettler, Susanna Lehtimaki & Nina Schwalbe
<http://dx.doi.org/10.2471/BLT.19.249664>

Child Care, Health and Development

Volume 46, Issue 5 Pages: 537-649 September 2020
<https://onlinelibrary.wiley.com/toc/13652214/current>
[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 108, Issue 3 September 2020
<https://onlinelibrary.wiley.com/toc/15326535/current>

Editorial

[The Changing Face of Oncology Research, Drug Development, and Clinical Practice: Toward Patient-Focused Precision Therapeutics](#)

Karthik Venkatakrishnan, Piet H. van der Graaf, Sarah A. Holstein
Pages: 399-404
First Published: 19 August 2020
Reviews

State of the Art

Artificial Intelligence and Mechanistic Modeling for Clinical Decision Making in Oncology

Sebastien Benzekry

Pages: 471-486

First Published: 18 June 2020

Abstract

The amount of “big” data generated in clinical oncology, whether from molecular, imaging, pharmacological, or biological origin, brings novel challenges. To mine efficiently this source of information, mathematical models able to produce predictive algorithms and simulations are required, with applications for diagnosis, prognosis, drug development, or prediction of the response to therapy. Such mathematical and computational constructs can be subdivided into two broad classes: biologically agnostic, statistical models using artificial intelligence techniques, and physiologically based, mechanistic models. In this review, recent advances in the applications of such methods in clinical oncology are outlined. These include machine learning applied to big data (omics, imaging, or electronic health records), pharmacometrics and quantitative systems pharmacology, as well as tumor kinetics and metastasis modeling. Focus is set on studies with high potential of clinical translation, and particular attention is given to cancer immunotherapy. Perspectives are given in terms of combinations of the two approaches: “mechanistic learning.”

Clinical Therapeutics

July 2020 Volume 42, Issue 7, p1137-1424

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 17 Issue 4, August 2020

<https://journals.sagepub.com/toc/ctja/17/4>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 5 Sep 2020]

[No new digest content identified]

Contemporary Clinical Trials

Volume 95 August 2020

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/95/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 3, Issue 4 / August 2020

<https://www.liebertpub.com/toc/crispr/3/4>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 8, issue 3, September 2020

<https://link.springer.com/journal/40142/volumes-and-issues/8-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2020 - Volume 33 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currrenttoc.aspx>

[Reviewed earlier]

Developing World Bioethics

Volume 20, Issue 2 Pages: 61-114 June 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 30, Issue 5, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 14 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 44, Issue 3 Pages: 433-618 July 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 21 Issue 9 3 September 2020

<https://www.embopress.org/toc/14693178/current>

Science & Society 1 September 2020

[**The second coming : The comeback of the live vaccines**](#)

Anthony King

Live vaccines are gradually replaced by protein-based vaccines given the latter's better safety. But live vaccines seem to be more efficient via stimulation of the innate immune system.

Emerging Infectious Diseases

Volume 26, Number 9—September 2020

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 32 September 2020

<https://www.sciencedirect.com/journal/epidemics/vol/32/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 42, Issue 4 Pages: 1-40 July–August 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

Pregnant Women Covid-19 Vaccine Challenge Trials Lotteries

[Reviewed earlier]

The European Journal of Public Health

Volume 30, Issue 4, August 2020

<https://academic.oup.com/eurpub/issue/30/4>

[Reviewed earlier]

Expert Review of Vaccines

Vol 19 (7) 2020

<https://www.tandfonline.com/toc/ierv20/current>

Review

[A systematic review of vaccine availability at the national, district, and health facility level in the WHO African Region](#)

To describe vaccine stock-outs at national, district, and health facility levels in the WHO African region.

Chinwe Juliana Iwu , Ntombehle Ngcobo , Anelisa Jaca , Alison Wiyeh , Elizabeth Pienaar , Usuf Chikte & Charles S. Wiysonge

Pages: 639-651

Published online: 10 Aug 2020

Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication

Kimberly M. Thompson & Dominika A. Kalkowska

Pages: 661-686

Published online: 01 Aug 2020

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 5 Sep 2020]

[No new digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 5 Sep 2020]

[No new digest content identified]

Global Health Action

Volume 12, 2019 Issue 1

<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

2020 | Volume 8 | Number 2 June 30, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Public Health

Volume 15, 2020 Issue 9

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

Articles

Educating, training, and exercising for infectious disease control with emphasis on cross-border settings: an integrative review

Points of entry and other border regions educate, train, and exercise (ETEs) their staff to improve preparedness and response to cross-border health threats. However, no conclusive knowledge of these ETEs' eff...

Authors: Doret de Rooij, Evelien Belfroid, Christos Hadjichristodoulou, Varvara A. Mouchtouri, Jörg Raab and Aura Timen

Citation: Globalization and Health 2020 16:78

Content type: Review
Published on: 3 September 2020

Health Affairs

Vol. 39, No. 7 July 2020
<https://www.healthaffairs.org/toc/hlthaff/current>
Food, Income, Work & More
[Reviewed earlier]

Health and Human Rights

Volume 22, Issue 1, June 2020
<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>
Special Section: Mental Health and Human Rights

Recent Viewpoints

Human Rights Must Be Central to the International Health Regulations

Benjamin Mason Meier, Hanna E. Huffstetler, and Roojin Habibi,
26 August 2020

... As the IHR are revised anew to meet future global health threats, this Viewpoint examines the continuing importance of human rights in infectious disease control, balancing public health necessities and individual rights protections and reinforcing the connections between global health law and human rights law.

Health Economics, Policy and Law

Volume 15 - Issue 3 - July 2020
<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
[Reviewed earlier]

Health Policy and Planning

Volume 35, Issue 6, July 2020
<https://academic.oup.com/heapol/issue/35/6>
[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>
[Accessed 5 Sep 2020]
[No new digest content identified]

Human Gene Therapy

Volume 31, Issue 15-16 / August 2020
<https://www.liebertpub.com/toc/hum/31/15-16>
[Reviewed earlier]

Humanitarian Exchange Magazine

Number 77, March 2020

<https://odihpn.org/magazine/responding-to-ebola-in-the-democratic-republic-of-congo/>

Responding to Ebola in the Democratic Republic of Congo

by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world's second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA's flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Bajonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the work of the Bethesda counselling centre in Beni, which provides support to grieving families. Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by Adelicia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 16, Issue 7, 2020

<http://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 5 Sep 2020]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjurnal.com/content>

[Accessed 5 Sep 2020]

[No new digest content identified]

International Health

Volume 12, Issue 5, September 2020

<https://academic.oup.com/inthealth/issue/12/5>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 7, No 7 (2020) July 2020

<https://www.ijcmph.com/index.php/ijcmph/issue/view/64>

[Reviewed earlier]

International Journal of Epidemiology

Volume 49, Issue 3, June 2020

<https://academic.oup.com/ije/issue/49/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 13 Issue 3 2020

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/3>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

August 2020 Volume 97, p1-404

[https://www.ijidonline.com/issue/S1201-9712\(20\)X0009-9](https://www.ijidonline.com/issue/S1201-9712(20)X0009-9)

[Reviewed earlier]

JAMA Network**COVID-19 Update September 5, 2020**

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA

September 1, 2020, Vol 324, No. 9, Pages 823-908

<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint

Reopening K-12 Schools During the COVID-19 PandemicA Report From the National Academies of Sciences, Engineering, and Medicine

Kenne A. Dibner, PhD; Heidi A. Schweingruber, PhD; Dimitri A. Christakis, MD, MPH
free access

JAMA. 2020;324(9):833-834. doi:10.1001/jama.2020.14745

This Viewpoint summarizes recommendations made in a National Academies of Sciences, Engineering, and Medicine report about how to safely reopen and operate elementary and secondary schools for the 2020-2021 school year, which emphasizes the need for partnerships with public health officials and community leaders, and for transparent communication of risks and rewards that will result from every policy decision.

Editorial

COVID-19 and School Closures

Julie M. Donohue, PhD; Elizabeth Miller, MD, PhD

Viewpoint

Universal Masking in the United StatesThe Role of Mandates, Health Education, and the CDC

Lawrence O. Gostin, JD; I. Glenn Cohen, JD; Jeffrey P. Koplan, MD, MPH
free access has active quiz

JAMA. 2020;324(9):837-838. doi:10.1001/jama.2020.15271

This Viewpoint proposes legal and policy options for promoting universal face mask wearing in the US and, recognizing the limits of state-by-state implementation, proposes strengthening the authority, independence, and funding of the CDC to enact responses to this and future comparable public health emergencies.

Editorial

Universal Masking to Prevent SARS-CoV-2 Transmission—The Time Is Now

John T. Brooks, MD; Jay C. Butler, MD; Robert R. Redfield, MD

JAMA Pediatrics

August 2020, Vol 174, No. 8, Pages 741-812

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

JBI Database of Systematic Review and Implementation Reports

August 2020 - Volume 18 - Issue 8

<https://journals.lww.com/jbisrir/Pages/currrenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

August 2020 Volume 67, Issue 2, p145-308

[https://www.jahonline.org/issue/S1054-139X\(20\)X0007-3](https://www.jahonline.org/issue/S1054-139X(20)X0007-3)

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 68 (2020)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 45, Issue 4, August 2020

<https://link.springer.com/journal/10900/45/4>

[Reviewed earlier]

Journal of Development Economics

Volume 146 September 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/146/suppl/C>

Special Section on Child Development in India

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 15 Issue 3, July 2020

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

August 2020 - Volume 74 - 8

<https://jech.bmj.com/content/74/8>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 13, Issue 3 Pages: 179-249 August 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 1, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 31, Number 2, May 2020

<https://muse.jhu.edu/issue/42391>

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 22, Issue 4, August 2020

<https://link.springer.com/journal/10903/22/4>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 18, 2020_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[New issue; No digest content identified]

Journal of Infectious Diseases

Volume 222, Issue 3, 1 August 2020

<https://academic.oup.com/jid/issue/222/3>

[Reviewed earlier]

Journal of Medical Ethics

September 2020 - Volume 46 - 9

<http://jme.bmj.com/content/current>

Covid 19 Current Controversies

[Consent in the time of COVID-19](#) (10 June, 2020)

Helen Lynne Turnham, Michael Dunn, Elaine Hill, Guy T Thornburn, Dominic Wilkinson

[Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia](#) (2 July, 2020)

Søren Holm

[Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making](#) (9 July, 2020)

Yves S J Aquino, Nicolo Cabrera

[When patients refuse COVID-19 testing, quarantine, and social distancing in inpatient psychiatry: clinical and ethical challenges](#) (10 July, 2020)

Mark J Russ, Dominic Sisti, Philip J Wilner

Extended essays

[Human infection challenge studies in endemic settings and/or low-income and middle-income countries: key points of ethical consensus and controversy](#) (7 May, 2020)

Euzebiusz Jamrozik, Michael J Selgelid

[The Cohen problem of informed consent](#) (27 March, 2020)

William Simkulet

Journal of Patient-Centered Research and Reviews

Volume 7, Issue 3 (2020)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

August 2020 Volume 223, p1-236

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 5 Sep 2020]

[Reviewed earlier]

Journal of Public Health Management & Practice

September/October 2020 - Volume 26 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

Research Reports

Factors Affecting Implementation of Evidence-Based Practices in Public Health Preparedness and Response

Kennedy, Mallory; Carbone, Eric G.; Siegfried, Alexa L.; More

Journal of Public Health Management and Practice. 26(5):434-442, September/October 2020.

Journal of Public Health Policy

Volume 41, Issue 3, September 2020

<https://link.springer.com/journal/41271/41/3>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 2, Issue 2 (2019)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

September 2020 Volume 17 Issue 170

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

Journal of Travel Medicine

Volume 27, Issue 5, July 2020
<https://academic.oup.com/jtm/issue/27/5>
[Reviewed earlier]

Journal of Virology
September 2020; Volume 94, Issue 18
<http://jvi.asm.org/content/current>
[New issue; No relevant content identified]

The Lancet
Sep 05, 2020 Volume 396 Number 10252 p649-734, e22-e24
<https://www.thelancet.com/journals/lancet/issue/current>
Articles
[Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3](#)
Global Burden of Disease Health Financing Collaborator Network
Open Access

Online First
Comment
[COVID-19 vaccines: early success and remaining challenges](#)

Naor Bar-Zeev,
Tom Inglesby

...The two studies by Logunov and colleagues have several strengths. First, adenoviruses are ubiquitous, so humans might not be immunologically naive. Previous immunity to the vector might interfere with adenovirus-vectored COVID-19 vaccine efficacy. Indeed, findings of an adenovirus type 5-vectored COVID-19 vaccine trial suggested such immunity could affect COVID-19 responses.² In another study, a chimpanzee adenovirus vector was used, since humans will presumably be naive to at least the first dose.³ Logunov and colleagues used immunologically distinct (heterologous) vectors in their two-dose (prime-boost) regimen. They investigated cross-vector heterologous immunity and previous antivector adenovirus immunity, and neither affected COVID-19 immunogenicity.

A second strength is the threshold for neutralisation used in the two studies. Neutralisation assays vary from study to study. Neutralisation is tested by examining whether plasma from a recently vaccinated individual can prevent cellular damage on in-vitro exposure of cells to SARS-CoV-2. Both the degree of such protection (how many damaged cells are allowed) and the dose of the infecting virus vary across studies. Expecting a vaccine to result in less than complete neutralisation is not inherently wrong but sets the bar low and makes it easier to claim neutralising activity. In Logunov and colleagues' studies, however, the threshold for neutralisation was set high in two regards: the inoculating viral dose was large, and no arising cellular damage was allowable. Essentially, the assay was set at full neutralisation. This high bar implies these researchers took an a-priori risk that their vaccine might fail the test. It did not. It remains to be seen if other manufacturers will set a similar high standard.

A third strength is that the vaccine, similar to other adenovirus-vectored and mRNA COVID-19 vaccines before it,^{2 3, 4} induced broad immune responses. Although not specifically discussed, the results imply a T-helper-1-cell-weighted response that might be important for vaccine safety, potentially reducing the risk of antibody-dependent enhanced disease.⁵

A fourth strength was development of two vaccine formulations, frozen and lyophilised. A lyophilised formulation could mean stability within the existing global vaccine refrigerated cold chain that is needed to maintain vaccine efficacy from factory to recipient, a hurdle other vaccines are yet to address. Although more costly to produce at scale, product stability will maximise reach in remote terrain, a must if universal and equitable coverage is to be achieved.

Some limitations of the studies by Logunov and colleagues are notable. In the study of the frozen vaccine formulation, the population included young military personnel. Soldiers are likely to be fitter and healthier than the general population. Moreover, in older adults, immune senescence might make vaccines less immunogenic, and this age group was absent from this study. Sex imbalance occurred in the study arms because there was no random allocation. A control arm was conspicuously absent. Two participants were of Asian descent, with the rest of the participants of white European ethnic origin. Clearly, much more remains to be learned from the phase 3 randomised trial planned to include 40 000 civilian volunteers and, hopefully, broadly inclusive of groups at risk...

Online First

Articles

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y Logunov, et al

Summary

Background

We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S). We aimed to assess the safety and immunogenicity of two formulations (frozen and lyophilised) of this vaccine.

Methods

We did two open, non-randomised phase 1/2 studies at two hospitals in Russia. We enrolled healthy adult volunteers (men and women) aged 18–60 years to both studies. In phase 1 of each study, we administered intramuscularly on day 0 either one dose of rAd26-S or one dose of rAd5-S and assessed the safety of the two components for 28 days. In phase 2 of the study, which began no earlier than 5 days after phase 1 vaccination, we administered intramuscularly a prime-boost vaccination, with rAd26-S given on day 0 and rAd5-S on day 21. Primary outcome measures were antigen-specific humoral immunity (SARS-CoV-2-specific antibodies measured by ELISA on days 0, 14, 21, 28, and 42) and safety (number of participants with adverse events monitored throughout the study). Secondary outcome measures were antigen-specific cellular immunity (T-cell responses and interferon- γ concentration) and change in neutralising antibodies (detected with a SARS-CoV-2 neutralisation assay). These trials are registered with [ClinicalTrials.gov](https://clinicaltrials.gov), [NCT04436471](https://clinicaltrials.gov/ct2/show/NCT04436471) and [NCT04437875](https://clinicaltrials.gov/ct2/show/NCT04437875).

Findings

Between June 18 and Aug 3, 2020, we enrolled 76 participants to the two studies (38 in each study). In each study, nine volunteers received rAd26-S in phase 1, nine received rAd5-S in phase 1, and 20 received rAd26-S and rAd5-S in phase 2. Both vaccine formulations were safe and well tolerated. The most common adverse events were pain at injection site (44 [58%]), hyperthermia (38 [50%]), headache (32 [42%]), asthenia (21 [28%]), and muscle and joint pain (18 [24%]). Most adverse events were mild and no serious adverse events were detected. All participants produced antibodies to SARS-CoV-2 glycoprotein. At day 42, receptor binding domain-specific IgG titres were 14 703 with the frozen formulation and 11 143 with the lyophilised formulation, and neutralising antibodies were 49·25 with the frozen formulation and 45·95 with the lyophilised formulation, with a seroconversion rate of 100%. Cell-mediated responses were detected in all participants at day 28, with median cell proliferation of 2·5% CD4+ and 1·3% CD8+ with the frozen formulation, and a median cell proliferation of 1·3% CD4+ and 1·1% CD8+ with the lyophilised formulation.

Interpretation

The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.

Funding

Ministry of Health of the Russian Federation.

The Lancet Child & Adolescent Health

Aug 2020 Volume 4 Number 8 p555-640, e26-e34

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Aug 2020 Volume 2 Number 8e380-e440

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Aug 2020 Volume 8 Number 8 e973-e1100

<http://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Aug 2020 Volume 20 Number 8 p875-992, e180-e214

<http://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Aug 2020 Volume 5 Number 8 e414-e459

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Aug 2020 Volume 8 Number 8 p743-830, e67-e69

<http://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 24, Issue 8, August 2020

<https://link.springer.com/journal/10995/24/8>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 40 Issue 6, August 2020

<http://mdm.sagepub.com/content/current>

[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 98, Issue 2 Pages: 223-617 June 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 585 Issue 7823, 3 September 2020

http://www.nature.com/nature/current_issue.html

[New issue; No digest content identified]

Nature Biotechnology

Volume 38 Issue 8, August 2020

<https://www.nature.com/nbt/volumes/38/issues/8>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 5 Sep 2020)

[No new digest content identified]

Nature Genetics

Volume 52 Issue 8, August 2020

<https://www.nature.com/ng/volumes/52/issues/8>
[Reviewed earlier]

Nature Medicine

Volume 26 Issue 8, August 2020

<https://www.nature.com/nm/volumes/26/issues/8>

Focus on COVID-19 and digital privacy

The COVID-19 pandemic has necessitated the acceleration of the development of digital technologies to monitor the spread of the outbreak. Emergency powers are being used to track not just individuals' health data, but other personal information. The image shows the data that are being monitored on people's cell phones, and the effects on healthcare are discussed in this focus issue on COVID-19 and digital privacy.

[Reviewed earlier]

Nature Reviews Genetics

Volume 21 Issue 8, August 2020

<https://www.nature.com/nrg/volumes/21/issues/8>

[Reviewed earlier]

Nature Reviews Immunology

Volume 20 Issue 8, August 2020

<https://www.nature.com/nri/volumes/20/issues/8>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 19 Issue 8, August 2020

<https://www.nature.com/nrd/volumes/19/issues/8>

[Reviewed earlier]

New England Journal of Medicine

September 3, 2020 Vol. 383 No. 10

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

Public Health Decision Making during Covid-19 — Fulfilling the CDC Pledge to the American People

Sonja A. Rasmussen, M.D., and Denise J. Jamieson, M.D., M.P.H.

The Tragedy of Measles

Perri Klass, M.D.

Although measles has always had serious complications, it was not necessarily treated seriously in popular culture, even before the MMR vaccine became available. But there is a harrowing measles tragedy from one of America's great tragedians, Eugene O'Neill.

Accelerating Development of SARS-CoV-2 Vaccines — The Role for Controlled Human Infection Models

Meagan E. Deming, M.D., Ph.D., Nelson L. Michael, M.D., Ph.D., Merlin Robb, M.D., Myron S. Cohen, M.D., and Kathleen M. Neuzil, M.D., M.P.H.

Pediatrics

Vol. 146, Issue 2 5 Sep 2020

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

Pharmaceutics

Volume 12, Issue 7 (July 2020) – 97 articles

<https://www.mdpi.com/1999-4923/12/7>

[Reviewed earlier]

PharmacoEconomics

Volume 38, Issue 8, August 2020

<https://link.springer.com/journal/40273/38/8>

[Reviewed earlier]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 5 Sep 2020)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 5 Sep 2020)

Economic influences on population health in the United States: Toward policymaking driven by data and evidence

Atheendar S. Venkataramani, Rourke O'Brien, Gregory L. Whitehorn, Alexander C. Tsai

Collection Review | published 02 Sep 2020 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003319>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 5 Sep 2020)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

Research Article

Mistrust of the medical profession and higher disgust sensitivity predict parental vaccine hesitancy

Rebekah Reuben, Devon Aitken, Jonathan L. Freedman, Gillian Einstein

Research Article | published 02 Sep 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0237755>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 5 Sep 2020]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

<http://www.pnas.org/content/early/>

[No new digest content identified]

Prehospital & Disaster Medicine

Volume 35 - Issue 4 - August 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 137 August 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/137/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

09 September 2020 Volume 287 Issue 1934

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 184, Pages 1-112 (July 2020)

<https://www.sciencedirect.com/journal/public-health/vol/184/suppl/C>

[Reviewed earlier]

Public Health Ethics

IN PROGRESS

Volume 13, Issue 1, April 2020

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 135 Issue 4, July/August 2020

<https://journals.sagepub.com/toc/phrg/135/4>

[Reviewed earlier]

Qualitative Health Research

Volume 30 Issue 11, September 2020

<http://qhr.sagepub.com/content/current>

Special Issue: International Health

[Reviewed earlier]

Research Ethics

Volume 16 Issue 1-2, January-April 2020

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 5 Sep 2020]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest articles

[No new digest content identified]

Risk Analysis

Volume 40, Issue 8 Pages: 1507-1690 August 2020

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 5 Sep 2020]

[No new digest content identified]

Science

04 September 2020 Vol 369, Issue 6508

<http://www.sciencemag.org/current.dtl>

Special Issue - Democracy in the Balance

Introduction to special issue

In flux and under threat

By Tage Rai, Brad Wible

Science 04 Sep 2020 : 1174-1175

Around the world, democracy is losing ground. Polarization and disinformation have rendered liberals and conservatives unable to agree on basic facts. State violence and suppression of citizens' rights are resurgent. Free and fair elections are being threatened.

In this special issue, we critically examine the state of democracy and how it must adapt to achieve its ideals in the 21st century. We need to meet the challenges and opportunities of living in increasingly multiethnic societies, of fostering democracy in a weakened international environment, of reducing inequality and elevating the political representation of the poor, and of organizing social movements and combating disinformation tactics in the digital age.

Advances in technology are making it easier to distort true voter representation through gerrymandering, and political campaigns continue to struggle with reaching voters and persuading them to participate. Worryingly, state violence, which has always been a core feature of the democratic experience for some, is spreading in democratic societies.

Twenty years ago, it seemed inevitable that democracy would reach every corner of the globe. In this moment, we are reminded that we must fight for democracy and work to improve it. A scientific understanding of the social and behavioral phenomena that underlie its operation will help us enhance democracy and, by doing so, improve human lives and societies globally.

Science Translational Medicine

02 September 2020 Vol 12, Issue 559

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

Social Science & Medicine

Volume 258 August 2020

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/258/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 5 Sep 2020]

[No new digest content identified]

Travel Medicine and Infectious Diseases

Volume 35 May–June 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/35/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 25, Issue 8 Pages: i-iv, 905-1042 August 2020

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 38, Issue 40 Pages 6191-6346 (11 September 2020)

<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/40>

[Reviewed earlier]

Vaccines — Open Access Journal

<http://www.mdpi.com/journal/vaccines>

(Accessed 5 Sep 2020)

[No new digest content identified]

Value in Health

August 2020 Volume 23, Issue 8, p979-1118

[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0010-6](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0010-6)

[Reviewed earlier]

* * * *

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The Atlantic

<http://www.theatlantic.com/magazine/>

Accessed 5 Sep 2020

[No new, unique, relevant content]

BBC

<http://www.bbc.co.uk/>

Accessed 5 Sep 2020

[No new, unique, relevant content]

The Economist

<http://www.economist.com/>

Accessed 5 Sep 2020

Babbage

The fast and the spurious—the dangers of rushing a covid-19 vaccine

Sep 2nd 2020

Forbes

<http://www.forbes.com/>

Accessed 5 Sep 2020

[No new, unique, relevant content]

Foreign Affairs

<http://www.foreignaffairs.com/>

Accessed 5 Sep 2020

The Tragedy of Vaccine Nationalism

Only Cooperation Can End the Pandemic

By Thomas J. Bollyky and Chad P. Bown

September/October 2020

Foreign Policy

<http://foreignpolicy.com/>

Voice

Trump's Vaccine Can't Be Trusted

If a vaccine comes out before the election, there are very good reasons not to take it.

Laurie Garrett

September 3, 2020,

The Guardian

<http://www.guardiannews.com/>

[No new, unique, relevant content]

New Yorker

<http://www.newyorker.com/>

Accessed 5 Sep 2020

[No new, unique, relevant content]

New York Times

<http://www.nytimes.com/>

Accessed 5 Sep 2020

Politics

Kamala Harris Says Trump Not Credible on Possible COVID-19 Vaccine

Democratic U.S. vice presidential candidate Kamala Harris said she would not take President Donald Trump's word alone on any potential coronavirus vaccine.

By Reuters Sept. 5

Politics

Race for Coronavirus Vaccine Pits Spy Against Spy

The intelligence wars over vaccine research have intensified as China and Russia expand their efforts to steal American work at both research institutes and companies.

By Julian E. Barnes and Michael Venutolo-Mantovani Sept. 5

Europe

Sanofi France Chief: Future COVID-19 Vaccine Seen Below 10 Euros

Sanofi's chief in France, Olivier Bogillot, said on Saturday that its future COVID-19 vaccine was likely to be priced below 10 euros per shot.

By Reuters Sept. 5

Asia Pacific

China's CNBG, Sinovac Find More Countries to Test Coronavirus Vaccines

China National Biotec Group (CNBG) and Sinovac Biotech Ltd said on Saturday they have each found two more countries to run late-stage clinical tests of their coronavirus vaccine candidates, as China steps up its efforts in the global race.

By Reuters Sept. 5

World

UN Assembly President: 'Inclusion Is Key' for Virus Vaccine

The president of the U.N. General Assembly is warning that a vaccine for COVID-19 must be made available to everyone who needs it because if just one country is left out the world will still face a crisis from the coronavirus.

By The Associated Press Sept. 4

Europe

UN: No Vaccine to Be Endorsed Before It's Safe and Effective

The head of the World Health Organization said the U.

By The Associated Press Sept. 4

Europe

WHO Chief Scientist: 'We Should See Vaccine Rollout by Mid-2021'

The World Health Organization is hopeful that a novel coronavirus vaccine will be ready internationally by mid-2021, its chief scientist said on Friday.

By Reuters Sept. 4

Europe

WHO's Tedros Says 'Vaccine Nationalism' Would Prolong Pandemic

WHO Director-General Tedros Adhanom Ghebreyesus said on Friday that "vaccine nationalism" would only slow the effort to quash the pandemic and called for vaccines to be used fairly and effectively.

By Reuters Sept. 4

Washington Post

<https://www.washingtonpost.com/>

Accessed 5 Sep 2020

[No new, unique, relevant content]

* * * *

Think Tanks et al

Brookings

<http://www.brookings.edu/>

Accessed 5 Sep 2020

[No new relevant content]

Center for Global Development [to 5 Sep 2020]

<http://www.cgdev.org/page/press-center>

Accessed 5 Sep 2020

[No new relevant content]

Chatham House [to 5 Sep 2020]

<https://www.chathamhouse.org/>

[No new relevant content]

CSIS

<https://www.csis.org/>

Accessed 5 Sep 2020

Commentary

The Risks of Misinformation and Vaccine Hesitancy within the Covid-19 Crisis

September 4, 2020 | By [Katherine E. Bliss](#), [J. Stephen Morrison](#)

Council on Foreign Relations

<http://www.cfr.org/>

Accessed 5 Sep 2020

[No new relevant content]

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 5 Sep 2020

[No new relevant content]

* * * *

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children's Hospital of Philadelphia [CHOP].

Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *